Because our discovered G9a-translational mechanism directly and ultimately determined AD-correlated proteomic or phosphoproteomic changes in diseased brain, MS1262 showed high specificity and efficacy for protecting AD patients from cognitive impairment and noncognitive disorders. The gene discussed is EHMT2; the disease is Alzheimer disease.